Full-Time

Director of Strategic Accounts

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Compensation Overview

$236k - $260k/yr

+ Uncapped Quarterly Commissions + Restricted Stock Units (RSUs)

Senior

Company Historically Provides H1B Sponsorship

Indianapolis, IN, USA + 3 more

More locations: Dallas, TX, USA | St. Louis, MO, USA | Kansas City, MO, USA

Candidates are preferred to be based in Dallas, St. Louis, Kansas City, or Indianapolis.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • BA in Business, Marketing or related field is required; MBA preferred.
  • Minimum 5 years experience in strategic Oncology sales to aforementioned targets across the United States preferred.
  • Market knowledge and experience in Pathology, Oncology & Laboratory sales preferred.
  • Requires 75% travel.
Responsibilities
  • Become an expert in Natera’s technology and service offerings and be able to represent the company and its business interests at the highest levels with: KOL Physicians, Hospital and System Medical Directors and C-Suite level targets.
  • Develop and execute plans to ensure rapid distribution of all products with minimal supervision.
  • Establish positive working relationships with all key customer segments (internal and external).
  • Educate and recruit Key Opinion Leaders from the Oncology/Hematology, Pathology & Surgical medical community.
  • The position requires assistance with recruitment and training of all Directors of Strategic Accounts (DSA’s).
  • Allocate time as defined with the VP, in the field with AD’s, RD’s, SAM’s and COS to provide direction and feedback to maximize potential collaboration opportunities.
  • Provide direction based on field input, market assessments and trends to develop an Area which is consistently implementing "Best Practices".
  • Attend local, regional, and national trade shows, meetings & trainings.
  • Educate and recruit Strategic Accounts and Lab Partners to offer Natera’s portfolio of tests.
  • Develop business plans based on sales goals, expectations and available resources, coordinating regional strategies and tactics with Natera Sales Teams.
  • Effectively work with Natera's clinical field sales team to help maximize potential business opportunities and partnerships.
  • Implement strategy based on field input, market assessments and trends to develop a plan which is consistently implementing "Best Practices".
  • Perform with a sense of urgency, with a focus on achieving exceptional revenue growth.
  • Play a critical role in the success of the organization.
Desired Qualifications
  • Background in medical or biological sciences is preferred.
  • Market knowledge and experience in oncology/Surgery/Pathology Laboratory Preferred.

Natera specializes in genetic testing and diagnostics within the healthcare sector, offering advanced testing solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. The company utilizes cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood, which helps detect minimal traces of cancer after treatment, guiding treatment decisions. One of their key products is the Signatera test, a custom ctDNA test for cancer patients, available through a remote access program. Natera also provides testing for organ health in transplant patients and offers a variety of tests for women's health, including the Panorama NIPT for prenatal screening. Their business model focuses on selling testing kits and services to healthcare providers and patients, often with insurance reimbursement. Natera distinguishes itself by combining specialized testing with genetic counseling services, allowing patients to receive personalized guidance remotely.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI adoption in genetic testing enhances Natera's prenatal and cancer diagnostics.
  • Remote healthcare trends expand the market for Natera's at-home genetic testing kits.
  • Advancements in liquid biopsy technologies benefit Natera's market reach and accessibility.

What critics are saying

  • Increased competition from companies like Lantheus Holdings may impact Natera's market share.
  • The sale of company stock by Natera's CFO might indicate potential internal concerns.
  • Adoption challenges for the Donor Quantity Score in Prospera Heart could affect its success.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for prenatal and cancer diagnostics.
  • The company offers unique tests like Signatera and Prospera Heart with Donor Quantity Score.
  • Natera provides remote genetic counseling, enhancing accessibility for patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

5%
Slater Sentinel
Apr 3rd, 2025
DnB Asset Management AS Invests $235,000 in Natera, Inc. (NASDAQ:NTRA)

DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).

TXBN
Mar 25th, 2025
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.

Simply Wall St
Mar 13th, 2025
Natera (NasdaqGS:NTRA) Welcomes Former National Cancer Institute Director Back to Board

Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.

Investing.com
Mar 10th, 2025
Natera launches HEROES trial for breast cancer treatment

Natera launches HEROES trial for breast cancer treatment.

Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.